Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1100+0.0300 (+2.78%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0800
Open1.0800
Bid1.0300 x 3000
Ask1.1600 x 2200
Day's Range1.0336 - 1.1100
52 Week Range1.0200 - 5.0700
Volume7,835
Avg. Volume24,122
Market Cap9.071M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-2.6740
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Benitec Biopharma Releases Q3 2022 Financial Results

    HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exch

  • PR Newswire

    Benitec Biopharma Discloses Q2 2022 Financial Results

    Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q2 ended December 31, 2021. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2021, with the U.S. Securities and Exchange Commission.

  • CNW Group

    /C O R R E C T I O N from Source -- Norra Metals Corp./

    Norra Metals Corp. ("Norra" or the "Company") (TSXV: NORA) (Frankfurt: 1KO) (OTC: NRRMF) intends to complete a non-brokered private placement, on a best efforts basis, of up to 10,000,000 units (the "Units") with a 20% over-allotment option at a price of $0.065 per Unit for gross proceeds of up to $650,000 (the "Offering").

Advertisement
Advertisement